PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY TYPE Market segmentation by type Comparison by type Systemic amyloidosis - Market size and forecast 2018-2023 Other amyloidosis - Market size and forecast 2018-2023 Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Increasing awareness about rare diseases Special drug designations Strategic alliances PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors AbbVie Inc. Allergan Plc Alnylam Pharmaceuticals Inc. Amgen Inc. Celgene Corp. GlaxoSmithKline Plc Ionis Pharmaceuticals Inc. Johnson & Johnson Services Inc. Pfizer Inc. Takeda Pharmaceutical Co. Ltd. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Type - Market share 2018-2023 (%) Exhibit 19: Comparison by type Exhibit 20: Systemic amyloidosis - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Systemic amyloidosis - Year-over-year growth 2019-2023 (%) Exhibit 22: Other amyloidosis - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Other amyloidosis - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by type Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Proportion of geriatric population in Asia 2009 and 2018 Exhibit 36: Asia - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Asia Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 39: ROW - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in ROW Exhibit 41: Key leading countries Exhibit 42: Market opportunity Exhibit 43: Prevalence/incidence of associated risk factors of amyloidosis Exhibit 44: Growth of geriatric population 2014-2018 (%) Exhibit 45: Cost of approved drugs for treatment of amyloidosis in the US Exhibit 46: Impact of drivers and challenges Exhibit 47: Drug designations Exhibit 48: Vendor landscape Exhibit 49: Landscape disruption Exhibit 50: Vendors covered Exhibit 51: Vendor classification Exhibit 52: Market positioning of vendors Exhibit 53: AbbVie Inc. - Vendor overview Exhibit 54: AbbVie Inc. - Business segments Exhibit 55: AbbVie Inc. - Organizational developments Exhibit 56: AbbVie Inc. - Geographic focus Exhibit 57: AbbVie Inc. - Key offerings Exhibit 58: AbbVie Inc. - Key customers Exhibit 59: Allergan Plc - Vendor overview Exhibit 60: Allergan Plc - Business segments Exhibit 61: Allergan Plc - Organizational developments Exhibit 62: Allergan Plc - Geographic focus Exhibit 63: Allergan Plc - Segment focus Exhibit 64: Allergan Plc - Key offerings Exhibit 65: Allergan Plc - Key customers Exhibit 66: Alnylam Pharmaceuticals Inc. - Vendor overview Exhibit 67: Alnylam Pharmaceuticals Inc. - Business segments Exhibit 68: Alnylam Pharmaceuticals Inc. - Organizational developments Exhibit 69: Alnylam Pharmaceuticals Inc. - Key offerings Exhibit 70: Alnylam Pharmaceuticals Inc. - Key customers Exhibit 71: Amgen Inc. - Vendor overview Exhibit 72: Amgen Inc. - Business segments Exhibit 73: Amgen Inc. - Organizational developments Exhibit 74: Amgen Inc. - Geographic focus Exhibit 75: Amgen Inc. - Key offerings Exhibit 76: Amgen Inc. - Key customers Exhibit 77: Celgene Corp. - Vendor overview Exhibit 78: Celgene Corp. - Business segments Exhibit 79: Celgene Corp. - Organizational developments Exhibit 80: Celgene Corp. - Geographic focus Exhibit 81: Celgene Corp. - Key offerings Exhibit 82: Celgene Corp. - Key customers Exhibit 83: GlaxoSmithKline Plc - Vendor overview Exhibit 84: GlaxoSmithKline Plc - Business segments Exhibit 85: GlaxoSmithKline Plc - Organizational developments Exhibit 86: GlaxoSmithKline Plc - Geographic focus Exhibit 87: GlaxoSmithKline Plc - Segment focus Exhibit 88: GlaxoSmithKline Plc - Key offerings Exhibit 89: GlaxoSmithKline Plc - Key customers Exhibit 90: Ionis Pharmaceuticals Inc. - Vendor overview Exhibit 91: Ionis Pharmaceuticals Inc. - Business segments Exhibit 92: Ionis Pharmaceuticals Inc. - Organizational developments Exhibit 93: Ionis Pharmaceuticals Inc. - Key offerings Exhibit 94: Ionis Pharmaceuticals Inc. - Key customers Exhibit 95: Johnson & Johnson Services Inc. - Vendor overview Exhibit 96: Johnson & Johnson Services Inc. - Business segments Exhibit 97: Johnson & Johnson Services Inc. - Organizational developments Exhibit 98: Johnson & Johnson Services Inc. - Geographic focus Exhibit 99: Johnson & Johnson Services Inc. - Segment focus Exhibit 100: Johnson & Johnson Services Inc. - Key offerings Exhibit 101: Johnson & Johnson Services Inc. - Key customers Exhibit 102: Pfizer Inc. - Vendor overview Exhibit 103: Pfizer Inc. - Business segments Exhibit 104: Pfizer Inc. - Organizational developments Exhibit 105: Pfizer Inc. - Geographic focus Exhibit 106: Pfizer Inc. - Segment focus Exhibit 107: Pfizer Inc. - Key offerings Exhibit 108: Pfizer Inc. - Key customers Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Vendor overview Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Business segments Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Organizational developments Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Geographic focus Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Key customers Exhibit 115: Validation techniques employed for market sizing Exhibit 116: Definition of market positioning of vendors  

AbbVie Inc., Allergan Plc, Alnylam Pharmaceuticals Inc., Amgen Inc., Celgene Corp., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.